KTE-C19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL): Outcomes in Patients Who Were Treated with Prior Blinatumomab in ZUMA-3

被引：1

作者：

Shah, Bijal D. ^{[1
]}

Oluwole, Olalekan O. ^{[2
]}

Baer, Maria R. ^{[3
]}

Bishop, Michael R. ^{[4
]}

Holmes, Houston ^{[5
]}

Schiller, Gary J. ^{[6
]}

Donnellan, William ^{[7
]}

O'Dwyer, Kristen M. ^{[8
]}

Mardiros, Armen ^{[9
]}

Rossi, John M. ^{[9
]}

Shen, Tong ^{[9
]}

Xue, Allen ^{[9
]}

Jain, Rajul K. ^{[9
]}

Vezan, Remus ^{[9
]}

Wierda, William G. ^{[10
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[2] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[3] Univ Maryland, Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA

[4] Univ Chicago Med, Chicago, IL USA

[5] Texas Oncol Baylor Charles A Sammons Canc Ctr, Dallas, TX USA

[6] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[7] Sarah Cannon Res Inst, Nashville, TN USA

[8] Univ Rochester, Rochester, NY USA

[9] Kite, Santa Monica, CA USA

[10] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2018年 / 18卷

关键词：

chimeric antigen receptor; acute lymphoblastic leukemia; CD19; blinatumomab;

D O I：

10.1016/j.clml.2018.07.015

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ALL-128

引用

页码：S184 / S184

页数：1

共 20 条

[1] KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results
Shah, Bijal D.
Bishop, Michael R.
Oluwole, Olalekan O.
Logan, Aaron C.
Baer, Maria R.
Donnellan, William B.
O'Dwyer, Kristen M.
Holmes, Houston
Arellano, Martha L.
Ghobadi, Armin
Pagel, John M.
Lin, Yi
Cassaday, Ryan D.
Park, Jae H.
Abedi, Mehrdad
Castro, Januario E.
DeAngelo, Daniel J.
Malone, Adriana K.
Mawad, Raya
Schiller, Gary J.
Rossi, John M.
Bot, Adrian
Shen, Tong
Goyal, Lovely
Jain, Rajul K.
Vezan, Remus
Wierda, William G.
BLOOD, 2021, 138 (01) : 11 - 22
[2] Kinetics of immune reconstitution after anti-CD19 chimeric antigen receptor T cell therapy in relapsed or refractory acute lymphoblastic leukemia patients
Wang, Ying
Li, Hujun
Song, Xuguang
Qi, Kunming
Cheng, Hai
Cao, Jiang
Shi, Ming
Yan, Zhiling
Jing, Guangjun
Pan, Bin
Sang, Wei
Wang, Xiangmin
Zhao, Kai
Chen, Chong
Chen, Wei
Zheng, Junnian
Li, Zhenyu
Xu, Kailin
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2021, 43 (02) : 250 - 258
[3] Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia
Gu, Runxia
Liu, Fang
Zou, Dehui
Xu, Yingxi
Lu, Yang
Liu, Bingcheng
Liu, Wei
Chen, Xiaojuan
Liu, Kaiqi
Guo, Ye
Gong, Xiaoyuan
Lv, Rui
Chen, Xia
Zhou, Chunlin
Zhong, Mengjun
Wang, Huijun
Wei, Hui
Mi, Yingchang
Qiu, Lugui
Lv, Lulu
Wang, Min
Wang, Ying
Zhu, Xiaofan
Wang, Jianxiang
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
[4] Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia
Runxia Gu
Fang Liu
Dehui Zou
Yingxi Xu
Yang Lu
Bingcheng Liu
Wei Liu
Xiaojuan Chen
Kaiqi Liu
Ye Guo
Xiaoyuan Gong
Rui Lv
Xia Chen
Chunlin Zhou
Mengjun Zhong
Huijun Wang
Hui Wei
Yingchang Mi
Lugui Qiu
Lulu Lv
Min Wang
Ying Wang
Xiaofan Zhu
Jianxiang Wang
Journal of Hematology & Oncology, 13
[5] Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
Locke, Frederick L.
Neelapu, Sattva S.
Bartlett, Nancy L.
Siddiqi, Tanya
Chavez, Julio C.
Hosing, Chitra M.
Ghobadi, Armin
Budde, Lihua E.
Bot, Adrian
Rossi, John M.
Jiang, Yizhou
Xue, Allen X.
Elias, Meg
Aycock, Jeff
Wiezorek, Jeff
Go, William Y.
MOLECULAR THERAPY, 2017, 25 (01) : 285 - 295
[6] Anti-CD19 CAR T as a feasible therapy for refractory/relapsed mixed phenotype acute leukemia patients
Li, Xiangqun
Chen, Kylan
Zhang, Hailong
Zhang, Xian
Yang, Junfang
Liu, Jing
Zheng, Jianwei
Dong, Fei
Zhu, Yongbo
Yu, Jiao
Zhang, Haihong
Lu, Peihua
Chen, Bo
PEDIATRIC BLOOD & CANCER, 2022, 69 (10)
[7] Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3
Shah, Bijal D.
Cassaday, Ryan D.
Park, Jae H.
Houot, Roch
Oluwole, Olalekan O.
Logan, Aaron C.
Boissel, Nicolas
Leguay, Thibaut
Bishop, Michael R.
Topp, Max S.
Tzachanis, Dimitrios
O'Dwyer, Kristen M.
Arellano, Martha L.
Lin, Yi
Baer, Maria R.
Schiller, Gary J.
Subklewe, Marion
Abedi, Mehrdad
Minnema, Monique C.
Wierda, William G.
DeAngelo, Daniel J.
Stiff, Patrick J.
Jeyakumar, Deepa
Mao, Daqin
Adhikary, Sabina
Zhou, Lang
Schuberth, Petra C.
Damico Khalid, Rita
Ghobadia, Armin
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (08)
[8] Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin's lymphoma
Jain, Michael D.
Bachmeier, Christina A.
Phuoc, Vania H.
Chavez, Julio C.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2018, 14 : 1007 - 1017
[9] Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD-19 chimeric antigen receptor T-cell therapy
Tambaro, Francesco Paolo
Khazal, Sajad
Nunez, Cesar
Ragoonanan, Dristhi
Tewari, Priti
Petropoulos, Demetrios
Kebriaei, Partow
Wierda, William George
Mahadeo, Kris Michael
CLINICAL CASE REPORTS, 2020, 8 (09): : 1678 - 1681
[10] Anti-CD19 chimeric antigen receptor T-cell therapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia Two case reports
Zhu, Yang-min
Wu, Zhao
Tan, You-ping
Du, Yuan-yuan
Liu, Zhi
Ou, Rui-ming
Liu, Shuang
Pu, Cheng-fei
Jiang, Jing
Wang, Jin-ping
Xiao, Lei
Zhang, Qing
MEDICINE, 2016, 95 (51) : e5676

← 1 2 →